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Abstract 
         Patients with malignant glioma have poor prognosis in spite of the advances in 
cancer therapy. Only 15% of the glioma patients survive more than five years after 
diagnosis. This is because the drug cannot reach the tumour site in sufficient amounts.  
          The aim of this project is to investigate the hypothesis that nanoemulsion 
formulations play an effective role as drug-delivery vehicles for the treatment of glioma. 
Two commercially available nanoemulsion formulations (Clinoleic TPN 20% and 
Intralipid TPN 20%) were used in this experiment. They were first characterised based on 
their size, zeta potential, pH and storage stability. Paclitaxel was used as the anti-cancer 
agent and the methods of loading efficiency determination (via spectrophotometry 
analysis) and Tissue culture were utilised to measure the effect of the formulation on 
glioma cell lines (U87-MG- grade IV and SVGP12 - normal glial cells).  
        Droplet size of the Clinoleic emulsion was increased from 254.1 nm to 264.7 nm 
when paclitaxel (6 mg/ml) was loaded into the formulation compared to drug-free 
formulation. Similarly with the Intralipid, the measured size was 283.3 nm and upon 
inclusion of 6mg/ml paclitaxel the size increased to 294.6 nm. The Polydispersity Index 
(PDI) of all the nanoemulsion formulations (Clinoleic and Intralipid) were lower than 0.2 
irrespective of paclitaxel concentration indicating that all nanoemulsion formulations used 
were homogenous. The pH values for the Clinoleic formulations (7.1-7.5) were slightly 
higher (i.e. formulation‟s basicity was higher  than those of the Intralipid formulations 
(6.5-6.9 .  he  eta Potential of  linoleic has a greater negative value than that of 
Intralipid.  he values for Intralipid are closer to neutral. When stored at 4   and room 
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temperature for two weeks major changes were observed in the characteristics of Intralipid 
formulations, but the Clinoleic formulations remained stable at both temperatures.  
     In the Clinoleic formulations 70.4 - 80.2% loading efficiencies were observed for 
paclitaxel. Conversely, lower loading efficiencies were obtained for the Intralipid 
formulations, being 44.2 – 57.38 %. Clinoleic loaded with paclitaxel successfully 
decreased the U87-MG cell viability to 6.4 ± 2.3 %, while Intralipid loaded with paclitaxel 
lowered the cell viability to 21.29 ± 3.82%. On the other hand, both nanoemulsions are 
less toxic to the normal glial cells (SVG-P12), decreasing the cell viability to 25-35%. 
This study suggests that nanoemulsions are useful and potentially applicable vehicles of 
paclitaxel for treatment of glioma. 
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List of Abbreviations  
 
ANOVA Analysis of variance 
DMSO Dimethyl Sulfoxide 
HPLC High Performance Liquid chromatography 
MEM Minimum Essential Media 
MTT 
3-(4,5-Dimethlythiazol-2-yl)-2-5-
diphenyltetrazolium bromide 
O/W Oil in Water 
PBS Phosphate Buffer Saline 
PCS Photon Correlation Spectroscopy 
PDI Polydispersity Index 
PLL Poly-L-Lysine 
SD Standard Deviation 
SVG-P12 Normal glial cell line 
TEM Transmission Electron Microscopy 
TPN Total Parenteral Nutrition 
U87-MG Grade IV glioma cell line 
UV Ultraviolet 
ZP Zeta Potential 
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1.1 Cancer pathophysiology 
         Cancer can be defined as a large group of diseases in which some abnormal cells do 
not follow the standard rules of cell division and growth. Normal individual cells are not 
autonomous as they depend on signals from their external environment that instruct the 
cells whether to multiply, differentiate or die. By contrast the abnormal cancerous cells are 
resistant to these signals and hence they divide and proliferate uncontrollably. Almost 
90% of deaths due to cancer are because of metastasis which is the process of the tumour 
spreading to other locations of the body. A cancerous tumour originates from a single 
mutated abnormal cell. 
 
    Except reproductive cells, all cells divide and multiply by the process of mitosis. 
Mitosis is the nuclear and cellular division that produces two identical daughter cells; it 
involves Interphase, Prophase, Prometaphase, Metaphase, Anaphase and Telophase. 
Cancer is fundamentally a disease of mitosis as the normal rules of mitosis are ignored by 
the cancer cells. Cancer cells show aneuploidy, i.e., they have an abnormal number of 
chromosomes. 
The p53 gene controls the proper functioning of the mitotic cycle. However, in over 50% 
of incidences of cancer, the p53 gene is mutated. 
17 
 
 
Figure 1.1: Normal mitosis (shown in the centre) as compared to abnormal mitosis 
that occurs due to absence of Mitotic Checkpoints (MC) leading to aneuploidy 
(Source: Schvartzman et al, 2010).  
      
     The formation and development of a tumour depends on external and internal factors. 
External factors include all of the environmental factors that may cause cancer such as 
tobacco, alcohol, radiation, chemicals and viral infections. Internal factors may involve the 
genetic background such as hormones, inherited mutations and immune system 
abnormalities.  One in every three individuals is susceptible to and shows signs of cancer. 
However, the rate of incidence varies significantly among countries suggesting that either 
some of these populations carry cancer-susceptibility genes or the external environmental 
factors contribute to their high cancer incidence rates.  
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 Cancer can arise in people from any age group (Figure 1.2), but it is more common 
amongst the elderly individuals (over 65 years of age).  
 
Figure 1.2: Relationship between age and the incidence of cancer.  
(Source: Howlander et al, 2011).  
 
       Hanahan and Weinberg (2000) proposed a model of the six hallmarks of cancer 
describing how the cancerous cells boost their growth and proliferation (Figure 1.3). These 
hallmarks are: 
- Cancer cells are immortal; they possess the quality of constant replication. 
- Cancer cells produce growth factors from oncogenes.  
- Cancer cells ignore anti-growth signals from the Tumour suppressor genes.  
19 
 
- Cancer cells are resistant to apoptosis.  
- Cancer cells may cause the formation of new blood vessels (angiogenesis). 
- Cancer cells exhibit Metastasis (spread to other locations in the body). 
 
 
Figure 1.3: The six hallmarks of Cancer. (Source: Hanahan et al, 2000). 
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1.2 Glioma 
        The brain is the most complex organ of the body and it is also one of the most 
essential organs. It is the centre of the Nervous system and is made up of billions of cells 
called neurons. All body functions (voluntary or involuntary) are controlled by the brain. 
The brain and the spinal cord form the Central Nervous System (CNS). The brain is 
divided into three major parts: Cerebral cortex (cerebrum – split into right and left 
hemispheres), cerebellum and brainstem (Figure 1.4). 
 
Figure 1.4: The major parts of the brain; primarily differentiated into the cerebrum, 
cerebellum and the brainstem.  (Source: Nieuwenhuys et al, 2008). 
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The cerebral cortex is sub-divided into the frontal lobe, parietal lobe, occipital lobe and 
temporal lobe. There is also a ventricular system in the brain. Ventricles are cerebrospinal 
fluid-filled spaces between the cerebrum and the brainstem. There are four such ventricles: 
the right and left ventricles (one in each cerebral hemisphere), third ventricle and fourth 
ventricle. 
 
         A glioma is a neoplasm (or tumour) that originates in the brain or the spine. In spite 
of advances in cancer therapy, most of the patients with malignant glioma have poor 
prognosis.  Most brain tumours develop from cancerous „glial cells‟ and are hence called 
gliomas. Gliomas are classified by cell type, grade or location. Every year in Western 
Europe, North America and Australia, there are about 6–11 new cases of primary 
(originating in the brain) glioma tumours per 100,000 populations in men and 4–11 new 
cases in women (Ohgaki H. et al, 2005). In 2011, in the United States alone there were 
22,340 new cases of Glioma and 13,110 deaths due to this disease. Only 15% of the 
people diagnosed with Glioma survive more than five years after diagnosis in the UK 
(Cancer Research UK). Gliomas are less common in other parts of the world.  
    The grade of glioma is verified by performing a pathological evaluation of the tumour. 
According to the World Health Organisation (WHO) gliomas are classified into four 
grades, from grade I (least advanced) to grade IV (most advanced). 
 
 Low-grade gliomas [WHO grades I and II] are not anaplastic, i.e., the cells are well-
distinguished. These are slow-growing malignant tumours which are less aggressive 
and hence the patients have better prognosis when compared to grades III and IV. Low 
22 
 
grade gliomas are quite common in children (about 50-70% of the cases). In the UK, 
there are around 4500 new cases of Glioma every year; 20% out of these tumours are 
low-grade gliomas. 
 
 High-grade [WHO grades III and IV] gliomas are anaplastic (lack of differentiation 
in cancerous cells). These are malignant tumours that have a very poor prognosis 
(Siew-Ju, et al 2007).                         
 
 Gliomas are also categorized according to the histological cell features: 
 Astrocytomas are neoplasms that originate from star-shaped brain cells called 
astrocytes. They can be located anywhere in the brain but are mostly found in the 
frontal lobe of the cerebrum. Astrocytomas are characterized by their slow growth, 
cyst formation and invasion of the surrounding tissue. Glioblastoma multiforme is the 
most common astrocytoma and it is also the most aggressive type of all gliomas 
(Grade IV). 
 
 Ependymomas is a type of tumour that originates from the ependymal tissue of the 
central nervous system. It is usually seen in the fourth ventricle (Figure 1.4) but can 
sometimes spread to the spinal cord. Rarely, ependymomas originate in the spinal 
cord. Ependymomas account for nearly 6% of all primary brain tumours. 
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 Oligodendrogliomas are neoplasms that arise from the oligodendrocytes of the brain. 
They most commonly originate in the four lobes on the cerebral cortex. Although it 
can occur in children, it is mostly seen in adults. 
Some tumours are of a „mixed‟ category and contain a mixture of glial cells, e.g. 
oligoastrocytomas. 
 
          The cerebrum is separated from the cerebellum by a membrane called the tentorium 
cerebelli (Figure 1.5). Thus, gliomas can also be classified according to whether they are 
located above or below the tentorium (Larjavaara et al, 2007).  
 
 
Figure 1.5: The Supratentorial and Infratentorial regions as divided by the 
tentorium cerebelli. (Source: Carter et al., 2009).  
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 Supratentorial gliomas are where the tumour originates in the cerebrum, above the 
tentorium. These tumours are commonly seen in adults. Supratentorial tumours 
account for about 80% of all intra-cranial tumours that are newly diagnosed. These are 
mostly seen in adults although they are highly common in infants who are less than a 
year old. 
 
 Infratentorial  gliomas are where the tumour originates below the tentorium, in the 
cerebellum and these are commonly seen in children. In fact, infratentorial gliomas 
account for 50-55% of all gliomas seen in children. Infratentorial tumours are seen 
most frequently in the cerebral hemispheres, followed by the brainstem and the fourth 
ventricle (Gusnard, 1990). 
 
 
 Pontine gliomas (or brainstem gliomas) are where the tumour is found in the pons of 
the brainstem. These are very aggressive and hard to treat as the pons controls 
important functional centres in the brain such as the breathing centre. These gliomas 
occur mostly in children (Angelini et al, 2011).  
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1.3 Therapeutic options for Gliomas 
                     
         The therapeutic options for glioma depend on the grade, location, size and cell type 
of glioma. Usually, surgery, chemotherapy and radiation therapy are all used in 
conjunction. Chemotherapy ends the growth of cancer cells by utilizing drugs, either by 
killing the cells or by stopping them from division. Common drugs used for glioma are 
temozolomide, vincristine and carmustine (Dall‟oglio et al, 2008). They are administered 
either orally or intravenously.  
However despite the best possible treatment with these drugs, most patients still show 
poor prognosis. 
 
       Malignant gliomas are vascular tumours and the main reason for their progression in 
the brain is angiogenesis (i.e. formation of new blood vessels) which involves endothelial 
cell proliferation, migration, reorganisation of extracellular matrix and tube formation 
(Rahman et al, 2010).
  
Bevacizumab, Cediranib, Sorafenib and Thalidomide are potent 
anti-angiogenic drugs. 
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         Another problem that most drugs encounter is the blood brain barrier (BBB). The 
BBB is characterized by relatively impermeable endothelial cells with tight junctions, 
preventing the passage of water-soluble molecules from the blood circulation into the 
CNS. Thus, most drugs fail to cross the BBB effectively and hence do not reach the target 
area in the brain in sufficient concentrations. 
 
Figure 1.6: The tight junctions at the BBB that do not allow water-soluble molecules 
to pass. (Source: Abbott et al, 2006).  
             Another major problem is the reticuloendothelial system (RES), also known as the 
Mononuclear phagocyte system. When a large foreign particle (drug) is injected into the 
body on its own, the RES views the drug as a toxic substance, causing the phagocytic cells 
of the RES to engulf the drug rendering them ineffective. Most of the drug is lost due to 
27 
 
this and hence it fails to reach the tumour site in the brain.  This can be avoided if the 
droplet size of the particles is in nm.  
Nanotechnology may help the drug to escape the RES as nanoparticles like nanoemulsion 
formulations, liposomes, niosomes are made of phospholipids (the same materials that the 
body cells are made from) or similar materials so the RES cells might not view them as 
toxic substances, providing that the formulation is robustly optimized (Eccleston, 2006). 
Hence, the drug might be able to reach the tumour site in larger concentrations. 
Nanoemulsion formulations may also help in enhancing the permeability of these drugs 
across the BBB as due to their extremely small size they might be able to pass through the 
BBB in advanced cases of glioma (Garcia-Garcia, 2005).  
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1.4 Nanoemulsion formulations 
               An emulsion is a heterogeneous preparation of two or more immiscible liquids, 
one of which is dispersed uniformly as fine droplets throughout the other. The phase 
present as droplets is known as the dispersed (internal) phase, while the surrounding liquid 
is known as the continuous (external) phase. An emulsion may be described as a 
macroemulsion, microemulsion or a nanoemulsion based on the droplet size of the 
dispersed phase. Nanoemulsions can be defined as oil-in-water (o/w) or water-in-oil (w/o) 
emulsions with mean droplet diameters ranging from 50 to 1000 nm. Usually, the average 
droplet size of nanoemulsions is between 100 and 500 nm. Droplet size less than 100 nm 
is not recommended as it is difficult to accommodate the drug in sufficient concentrations 
(Jong et al, 2008) 
 
Figure 1.7: Nanoemulsion [A] and a macroemulsion [B]. The translucent appearance 
of the nanoemulsions is attributed to the nano size of the dispersed droplets.   
(Source: Shah et al, 2010). 
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       Nanoemulsions were first developed over 20 years ago and as shown in Figure 1.7, 
they appear transparent (or translucent) because of their inability to scatter light 
(McClements, 2002). To be able to scatter light a particle must be more than one-fourth 
the size of the wavelength of visible light and hence nanoemulsions are transparent due to 
their small size. The terms sub-micron emulsion and mini-emulsion are also used as 
synonyms for nanoemulsions.  
 
      Nanoemulsions are commonly prepared using two methods:  high-energy methods and 
low-energy methods. The high-energy methods of High-pressure homogenization and 
Microfluidization are used at both laboratory and industrial scale, as they are very 
effective in reducing the droplet size of the dispersed phase. Low-energy methods like the 
Phase-inversion temperature technique and spontaneous emulsification method are used 
when macromolecules like proteins and nucleic acids are involved so that heat generated 
that might cause macromolecule degradation is avoided. In High-pressure 
homogenization, the crude mixture of the aqueous and oil phase is passed through a small 
orifice at an operating pressure of 500-5000 psi, where the mixture is exposed to extreme 
turbulence. This produces a finely-dispersed emulsion with a very small droplet size 
(Panayiotis et al, 2008). 
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Figure 1.8: The technique of High-pressure homogenization for preparation of 
Nanoemulsions.  (Source Shah et al, 2010).  
 
               Similarly, in the process of Microfluidization a solution of oil and water is 
pumped into the Microfluidization processor under an immense pressure ranging from 
1500 to 40000 psi. The mixture is then passed through an extremely small orifice (smaller 
than the diameter of a human hair follicle) at a very high speed (e.g. hundreds of meters 
per second). This creates a considerably high shear rate, causing highly efficient droplet 
size reduction (Jafari, 2007). But these formulations are not stable for long durations.  
 
           In the low energy method of Phase-inversion temperature technique, an oil-in-water 
emulsion transforms to a water-in-oil emulsion as the temperature rises and vice versa. 
When the preparation is made above the phase inversion temperature and followed by 
rapid cooling it produces emulsions that have very fine droplet size and long-term stability 
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(Forster et al, 1990). In 1878, Johannes Gad discovered the spontaneous emulsification 
method (also known as the Ouzo effect). In this method a hydrophobic essential oil is mixed 
with a water-miscible solvent (e.g. ethanol) and it spontaneously forms an oil-in-water emulsion 
with minimal stirring (Theissen, 1999). 
 
              An emulsion is said to be stable when the dispersed droplets retain their nature 
and remain evenly distributed throughout the continuous phase for a long duration. 
Emulsions are susceptible to a number of instability problems like coalescence, 
flocculation, creaming and breaking (Figure 1.9). Coalescence is a process in which two or 
more droplets combine to form a larger droplet upon contact, while flocculation is when 
multiple droplets adhere to each other to form clusters of droplets without merging to form 
a single large droplet. Creaming occurs when the dispersed phase either migrates upwards 
or sinks downwards (sediments) in the mixture. Emulsions are also prone to breaking due 
to surface tension. 
 
Figure 1.9: A presentation showing the instability manifestations of emulsions. 
(Source: Alvarado et al, 2011). 
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                       These instability problems can be overcome by using emulsifiers (i.e. 
emulsifying agents). The most common type of emulsifiers is the surface active agents 
(surfactants). Surfactants are organic amphiphilic compounds that lower the surface 
tension between the two immiscible liquids of the emulsion by coating the dispersed phase 
droplets (Figure 1.10) and hence increasing the emulsions kinetic stability. Polysorbate 20 
(Polyethylene glycol sorbitan monolaurate) and ceteareth 20 (C16~18 fatty alcohol 
polyoxyethylene ether) are two examples of emulsifying agents.  
   
 
Figure 1.10: Surfactant molecules coating the surface of the oil droplet in an 
emulsion. (Source: Lawrence et al, 2000).  
             
            Unlike microemulsions (which are thermodynamically stable), nanoemulsions are 
only kinetically stable. A chemical substance is said to be thermodynamically stable (or in 
thermodynamic equilibrium) when it is in its lowest energy state, i.e. it is in complete 
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equilibrium with its surroundings. A thermodynamically stable substance will not change 
unless energy in some form is provided. Kinetic stability on the other hand, is when a 
chemical substance reacts (changes) extremely slowly and remains constant over a long 
period of time.  However the long-term physical stability of nanoemulsions, due to their 
small droplet size and non-coalescent properties, makes them unique and they are 
sometimes referred to as “approaching thermodynamic stability” (Bouchemal et al, 2004).   
 
       Nanoemulsions can be formulated as liquids, sprays, foams, creams, ointments and 
gels and are used extensively in manufacturing cosmetics, pastes, pharmaceuticals etc. 
They are used especially as controlled drug-delivery vehicles for poorly water soluble 
drugs. They are non-toxic and non-irritant in nature making them ideal vehicles for 
therapeutic agents (Aboofazeli, 2010).
  
 
          Although the term „nanoemulsion‟ was not coined then, phospholipid-stabilized 
soybean oil emulsions were first approved safe for intravenous administration for 
nutritional purposes over 40 years ago (Driscoll, 2006). The size range for these emulsions 
was in the „nano‟ scale (around 300 nm , making them the first nanoemulsion 
formulations used. Nowadays, nanoemulsions are routinely administered as „ otal 
Parenteral Nutrition‟.  
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1.5 Nanoemulsions for the treatment of Glioma 
       Paclitaxel is a naturally occurring diterpene alkaloid occurring in the bark of the 
Pacific Yew tree, Taxus brevifolia. It was discovered in 1967 by Monroe E. Wall and 
Mansukh C. Wani as the outcome of the investigation of over 12,000 natural compounds 
for anti-cancer activity by the U.S. National Cancer Institute. Paclitaxel inhibits mitosis by 
disrupting microtubule integrity, thereby causing cell death (Sheng et al, 1999). The 
chemical structure of Paclitaxel is shown in Figure 1.11.  
 
 
Figure 1.11: Structure of paclitaxel (2α,4α,5β,7β,10β,13α)-4,10-bis(acetyloxy)-13-
{[(2R,3S)- 3-(benzoylamino)-2-hydroxy-3-phenylpropanoyl]oxy}- 1,7-dihydroxy-9-
oxo-5,20-epoxytax-11-en-2-yl benzoate. (Source: Surapaneni et al, 2012). 
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       In the last 15-20 years Paclitaxel has been widely used in anti-cancer therapy, 
especially against ovarian and breast cancer. Terzis et al (1997) tested Paclitaxel for its 
anti-migrational, anti-invasive and anti-proliferative effect on human glioma cell lines and 
found that cells showed nuclear fragmentation, indicating an induction of apoptosis. The 
only drawback of Paclitaxel is that it is poorly soluble in water and needs an appropriate 
delivery vehicle for intravenous administration. In a range of studies Cremophor EL was 
used as the non-aqueous delivery vehicle but it caused some serious side-effects such as 
hypersensitivity reactions, nephrotoxicity and neurotoxicity (Singla et al, 2002). Thus, 
provision of safe alternative vehicles for this drug is crucial.  
 
        Recently, nanoemulsions formulations have been used as delivery vehicles for 
Paclitaxel. Paclitaxel readily dissolves in the dispersed lipid phase and can be easily 
administered intravenously due to the external aqueous phase.  Zhao et al (2010), tested 
magnetic nanoparticles loaded with Paclitaxel in vitro and in glioma-bearing rats and 
found that the nanoparticles successfully delivered the Paclitaxel to the glioma and 
boosted its anti-tumour activity.  
 
               In this project, two commercially available nanoemulsions that are routinely used 
in total parenteral nutrition (TPN) were used to solubilise Paclitaxel for applications on 
glioma cell lines. The nanoemulsions are the Intralipid TPN (Fresenius Kabi, Germany) 
and the ClinOleic TPN (Baxter, USA), which are lipid nanoemulsions having different 
types of excipients. Dr Elhissi‟s research group have shown that both of these 
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nanoemulsions are suitable for solubilising the highly hydrophobic antifungal drug 
amphotericin B and formulations have been shown to generate inhalable aerosols by air-jet 
nebulisation (results have been submitted for publication).  
   
            Intralipid is composed of egg phospholipids, soybean oil and glycerine, while 
Clinoleic is made up of refined Olive oil (80%) and soybean oil (20%). Thus, the effects 
of different excipients in formulations were investigated in terms of formulation stability 
when Paclitaxel was included and with regard to the activity against the glioma cell lines. 
The findings were compared with paclitaxel by itself (without a delivery vehicle) in terms 
of anti-cancer effect and their toxicity against normal glial cells.  
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1.6 Working Hypothesis 
The main aim of this project is to test the hypothesis that Nanoemulsion formulations play 
an effective role as drug-delivery vehicles for hydrophobic drugs for the treatment of 
glioma.  
 
1.7 Aims of the study 
 To solubilize the hydrophobic anti-cancer agent paclitaxel into two different 
nanoemulsions formulations using various concentrations.  
 
 To characterize the nanoemulsion formulations on the basis of size, PDI, zeta 
potential and pH.  
 
 
 To carry out a stability study on both nanoemulsion formulations to investigate 
how the size, PDI, zeta potential and pH are affected by storing the formulations at 
different temperatures (room temperature and 4    over a period of two weeks.  
 
 To measure the loading efficiency of the nanoemulsion formulations to find the 
amount of drug loaded onto the nanoemulsion droplets.  
 
 
 To analyse the effect of these formulations on two glioma cell lines: U87-MG 
(normal glial cells) and SVG-P12 (grade IV glioma cells) 
38 
 
 
 
 
 
Chapter 2 : 
Materials and Methods 
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2.1 Materials 
2.1.1 Chemicals  
Supplier Products 
European Collection of Cell cultures 
(ECACC) 
U87-MG – Grade IV glioma cells 
SVG-P12 – normal glial cells 
Baxter Healthcare, USA ClinOleic TPN 20% 
Fresenius Kabi, Germany Intralipid TPN 20% 
Lonza, Switzerland 
Eagle‟s Minimum Essential media (EMEM  
(Lonza, Switzerland), Non-essential amino 
acid solution (100x), 2 mM L-glutamine 
Sigma Aldrich, UK 
Sodium Pyruvate, Phosphate Buffer Saline 
(PBS), Trypan Blue, Dextran (mol wt. 
5000), Poly-L-Lysine (PLL – mol wt 
70,000), Phosphate buffered saline, 
Paclitaxel, Dimethyl sulfoxide (DMSO).  
Fisher Scientific, UK 
Trypsin-EDTA solution, Absolute Ethanol, 
70% Ethanol, HPLC grade water 
Table 2.1: List of chemicals and their suppliers.  
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2.1.2 Equipment 
Zetasizer Nano zs (Malvern Instruments, UK), UV Spectrophotometer (Biowave, UK), 
Inverted microscope (Leica DMIL microsystems, Germany), Eclipse e200 Compound 
Microscope (Kodak, Japan), Corning 220 pH meter (Cole-Palmer, UK), pipette controller 
(Bio-gene, UK), Plate reader (Tecan, Switzerland), grant sub28 water bath (Grant 
instruments, UK), Galaxy 170s CO2 incubator (New Brunswick, Scotland), Laminar flow 
safety cabinet (Gelaire flow laboratories, Italy), Sigma 3-16 pk centrifuge (DJB Labcare, 
Germany), Whirlimixer (FESONS, UK),  
 
 
2.2 Methods 
 
2.2.1 Solubilisation of Paclitaxel in nanoemulsion formulations  
Paclitaxel was weighed in increasing amounts of 10, 20, 30, 40, 50 and 60 mg in separate 
glass vials using a weighing balance. 10 ml of Clinoleic or Intralipid was added to each 
glass vial. Glass vials were vortexed for 5 min and then kept in a bath sonicator at 40   for 
2 h.  
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2.2.2 Characterization of the Nanoemulsion formulations 
The Zetasizer Nanoseries zs (Malvern Instruments Ltd, UK) was used to measure the size 
and zeta potential of the nanoemulsions. The Zetasizer employs the principle of Photon 
correlation Spectroscopy (PCS) and accurately measures size in the range of 0.3 nm to 10 
µm.  40µl of nanoemulsion sample was mixed with 1 ml of HPLC grade water in a cuvette 
and the average of three readings was calculated. Specialized cuvettes were used to 
measure the zeta potential. The pH was measured using a pH meter. The pH meter was 
first calibrated using the provided pH 4 and pH 7 solutions and then the measurement of 
each nanoemulsion sample was conducted with washing the electrode by distilled water 
after each measurement.   
 
2.2.3 Stability studies 
Two sets of Formulations containing 0, 10, 30 and 60 mg of Paclitaxel each per 10 ml of 
nanoemulsion were prepared for both ClinOleic and Intralipid. One set of each was stored 
in the refrigerator (at 4ºC) and the second set of each was stored at room temperature 
(approximately 23ºC) for a period of 2 weeks. Their size, zeta potential and pH were 
regularly measured using the Zetasizer and the pH meter. Also, changes in their physical 
appearances were noted at the end of the 2 weeks.   
 
2.2.4 Calibration curve of Paclitaxel 
10 mg of paclitaxel was weighed in a 100 ml volumetric flask which was then filled with 
absolute ethanol to make the volume up to 100 ml (Stock solution). The solution was 
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stirred till the paclitaxel had completely dissolved in the ethanol. A serial dilution was 
then carried out by mixing the stock solution with ethanol as demonstrated in Table 2.2 –  
 
Concentration required 
(mg/100 ml) 
Amount of stock solution 
added (ml) 
Amount of ethanol added 
(ml) 
1  1 9 
2  2 8 
3  3 7 
4 4 6 
5  5 5 
6  6 4 
7  7 3 
8  8 2 
9  9 1 
10  10 0 
Table 2.2: A table showing the amount of stock solution and ethanol to be used to 
make serial dilutions.  
 
   The absorbance of each sample was measured at 270 nm and a calibration curve was 
plotted using the absorbance values obtained. The R
2
 value and calibration curve equation 
were obtained.  
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2.2.5 Loading efficiency using UV Spectrophotometer 
   The nanoemulsion formulations containing paclitaxel in the amounts of 10, 30 and 60 
mg per 10 ml were filtered through a 400 nm syringe filter. The residual (un-entrapped) 
crystals of paclitaxel left behind on the filter were dissolved in 10 ml of ethanol and their 
absorbance was measured at 270 nm. These absorbance values were then substituted in the 
equation obtained from the calibration curve to find out the amount of the un-entrapped 
drug in mg. The amount of un-entrapped drug was then subtracted from the total amount 
of drug added in the formulation to find out the quantity of the entrapped drug.  
 
2.2.6 Tissue culture  
      All tissue culture procedures were carried out aseptically in a Laminar flow safety 
cabinet and all materials were sterilised by autoclaving before use. Materials and media 
were warmed to 37º C before adding to the cells to avoid shock. Additionally, all the 
working surfaces were always cleaned with 70% ethanol before beginning the procedures. 
Experiments were carried out with passage numbers 13-31 and 7-18 for U87MG and 
SVGP12 respectively.   
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2.2.6.1 Preparation of tissue culture media 
A fresh bottle of media was prepared every week; separate bottles were used for U87MG 
and SVGP12 cell lines to avoid cross contamination.  
The ingredients for the complete media were as follows –  
EMEM (500 ml) + 10% foetal bovine serum (50 ml) + 2 mM L-glutamine (1 ml) + 1 mM 
sodium pyruvate (1 ml) + 0.1 mM (or 1%) non-essential amino acids  (1 ml) 
All materials were warmed to 37º C and mixed together under sterile conditions.  
 
2.2.6.2 Subculture and Re-suspension of Cells.  
    Cells were allowed to grow until they were 80-90% confluent (observed using an 
inverted light microscope). The U87MG cells were passaged every four days and the 
SVG-P12 cells were passaged every six days. The medium was first removed without 
disturbing the cells and then the cells were washed three times with PBS (10 ml). To 
detach the cells from the surface of the flask, a 0.25% trypsin-EDTA 
(Ethylenediaminetetraacetic acid) solution (1.5 ml) was added to the cells followed by 
incubation for 2-3 min at 37º C. Gentle agitation (tapping) to the culture flask was carried 
out to aid in the detachment of cells (verified by observing under the inverted 
microscope). Fresh media (2.5 ml) was added immediately to the detached cells to 
neutralize the effect of the trypsin-EDTA. The cell suspension was then centrifuged at 
1000 x g for 5 min. The supernatant (trypsin-EDTA + media) was discarded and required 
amount of fresh media (5-10 ml) was added to the cell pellet. A syringe and needle (23 G; 
0.6 mm x 25 mm) were used to re-suspend the cell pellet three times into the media, to 
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ensure the segregation of the cells. The cells were then added to new culture flasks at the 
appropriate seeding density.  
2.2.6.3 Cell Counting  
    Viable cell count was obtained by mixing 100 µl of the cell suspension (obtained after 
re-suspending the cells in fresh media, as described earlier) with 100 µl of trypan blue 
solution and 10 µl of the mixture was placed on the Neubauer Haemocytometer slide with 
a cover slip properly placed on top of the chamber. The non-viable cells had taken up the 
dye and were stained blue, while the viable cells appeared pale yellow.  
 
Figure 2.1: Neubauer Haemocytometer, each large square gives an area of 1 mm
2 
(1 
mm x 1 mm) with a depth of 0.1 mm. 
 
     Since, a large square is 1 mm
2 
in area; each large square provides 0.1 mm
3 
(1 mm x 1 
mm x 0.1 mm = 10
-4
 cm
3 
or 10
-4 
ml) of cells. The average number of viable cells per ml 
was obtained by measuring the number of viable cells in five large squares (then divided 
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by five to achieve average) and then multiplied by the dilution factor (x2,  as the cell 
suspension was diluted 1:1 with trypan blue solution) and x 10
4
.  
 
 
2.2.6.4 Seeding and Growth curves  
        The cells were seeded into 96 well plates for the MTT (3-(4,5-Dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) assay. To determine the most appropriate seeding 
density, growth curves were constructed. For the growth curves, cell suspensions were 
diluted to attain the densities of 10
3
, 10
4
 and 10
5
 cells per well. This was done using the 
following equation –  
 
C1 x V1 = C2 x V2 
 
Where, C1 is the cell viability count (obtained via using the haemocytometer) 
V1 is the total amount of cell suspension to be added to fresh media (unknown factor) 
C2 is the required cell density (10
3
, 10
4
 or 10
5
) and 
V2 is the total volume of cells + media required to fill the 96 wells. 
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Figure 2.2: A 96 well plate template. A 96 well plate is made up of twelve columns 
(numbered 1-12) and eight rows (A-H) 
 
The outer rows and columns (columns 1 and 12 and rows A and H) of the well plate were 
filled with Phosphate buffered saline (PBS) to avoid evaporation of the cell suspension. 
Columns 2-4 were filled with 200 µl each with the 10
3
 cells/well dilution and columns 5-8 
were filled with the 10
4
 cells/well dilution and columns 9-11 were filled with the 10
5
 
cells/well dilution.  
 
Five plates were prepared for both of the cell lines to check their growth over a seven-day 
period (Tue-Fri, Mon). They were incubated at 37º C for 24 h, 48 h, 72 h, 96 h and 144 h 
respectively. Each morning, 5 h before the end of the incubation times, 20 µl of MTT 
solution (5mg MTT dissolved per ml of PBS) was added to each well and kept back in the 
incubator. Viable cells reduce the MTT to a water-insoluble blue-coloured salt called 
formazan.  Then, at the end of the incubation time, all the MTT-containing media (220 µl) 
was pipetted out from the wells carefully, to avoid disturbing the blue formazan crystals at 
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the bottom of the plate. This was followed by addition of 100 µl of cell-culture grade 
DMSO (Dimethyl sulfoxide) to each well in order to solubilise the formazan crystals. The 
plates were then further incubated for 30 min at 37º C before spectrophotometric analysis 
at 612 nm using the Tecan microtitre plate reader. The absorbance readings were then 
plotted on a graph and the most appropriate seeding density was chosen for the 
cytotoxicity assays. 
 
2.2.6.5 Cytotoxicity assay (MTT) 
The cytotoxicity of the nanoemulsion formulations (with and without paclitaxel) and 
paclitaxel alone were tested on both the cell lines using the MTT assay. Their results were 
compared against the positive control Poly-L-lysine (PLL) and the negative control 
Dextran.  
A paclitaxel solution was made by adding 30 mg of the drug to 100 µl of ethanol. The 
formulation was kept in the water bath at 50º C until the paclitaxel was completely 
dissolved. Then 4.9 ml of media were added to the formulation to make up a final volume 
of 5 ml (and to achieve a drug concentration of 6mg/ml). Dextran and PLL solutions were 
made by adding the compounds directly to the media (as they are water soluble) to achieve 
a formulation with a concentration of 5 mg/ml. 
 
            Cells at the chosen seeding density were seeded into the inner rows of the 96 well 
plates. A different well plate was used for each formulation. The cells were then allowed 
to grow for 24 h. At the end of the 24 h, the formulations were added to all the inner wells 
of the plate in ascending concentrations. All the formulations were filtered using 0.4 µm 
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and 0.22 µm sterile syringe filters before addition to the plates to avoid contamination.  
The concentrations for the formulations are as follows – 
 
Column 
number 
2 3 4 5 6 7 8 9 10 11 
Concentration 
(mg/ml) 
0 0.001 0.005 0.01 0.05 0.1 0.5 1 3 6 
(Note: columns 1 and 12 contain PBS, hence no formulations were added to them) 
Table 2.3: Concentrations at which the controls/formulations were added to the 96-
well plates 
 
      The cells were then incubated for 72 h. MTT (20µl) was added to each well 5 h before 
the end of incubation. At the end of incubation time, the wells were emptied and 100 µl of 
DMSO was added to each well before their absorbance was read at 612 nm. The 
absorbance readings were then plotted on a graph to compare the toxicity of the 
compounds.  
 
2.3 Statistical analysis 
All the experiments were performed three times and the results were expressed as mean ± 
SD.  he student‟s t-test and one-way ANOVA tests were performed using SPSS 14.0 
software to calculate the significance between groups. A difference was considered to be 
significant if the P-value was less than 0.05. 
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         Paclitaxel is a widely-used anti-cancer agent. In the past 20-25 years paclitaxel has 
been proven to be effective against ovarian, lung, breast, head and neck cancers. Paclitaxel 
inhibits mitosis by disrupting microtubule integrity, thereby causing cell death (Sheng et 
al, 1999). But paclitaxel has a major drawback: it exhibits low aqueous solubility of less 
than 0.01 mg/ml (Surapaneni et al, 2012). Hence to be administered intravenously, 
paclitaxel requires a lipid-based delivery vehicle.  
         Nanoemulsion formulations are essentially oil droplets dispersed in an aqueous 
phase. Lipophilic drugs like paclitaxel readily dissolve in the lipid phase of nanoemulsions 
and can be easily administered intravenously due to the external aqueous phase.  
Nanoemulsions may help the drug to escape the RES as are made of phospholipids (the 
same materials that the body cells are made from) or similar materials as the RES cells 
might not view them as toxic substances, providing that the formulation is robustly 
optimized (Eccleston, 2006). Hence, the drug might be able to reach the tumour site in 
larger concentrations. Nanoemulsion formulations may also help in enhancing the 
permeability of these drugs across the BBB as due to their extremely small size they might 
be able to pass through the BBB in advanced cases of glioma (Garcia-Garcia, 2005). 
         The characteristics of nanoemulsions were studied before and after the inclusion of 
the anti-cancer drug Paclitaxel in order to evaluate the effect of the drug on the 
formulations. Intralipid TPN and Clinoleic TPN were the two commercially available 
nanoemulsion formulations used in these experiments and compared against each other. 
These two formulations differ in their compositions (Table 3.1) 
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Clinoleic TPN Intralipid TPN 
- Mixture of refined olive oil (approx. 
80%) and refined soybean oil 
(approx. 20%)   20 g 
- Essential fatty acids  4 g 
- Glycerol 2.25 g 
- Purified egg phosphatides  1.2 g 
- Sodium oleate  0.03 g 
- Refined soybean oil 20 g 
- Purified egg phospholipids 1.2 g 
- Glycerol anhydrous 2.2 g 
 
Table 3.1: Compositions of Clinoleic and Intralipid TPN.  
       Another important aspect that was investigated was the stability of these formulations. 
Any mixture of oil and water is susceptible to instabilities but these can be avoided (or 
delayed) by storing the formulations at the right temperature. Two sets of formulations of 
 linoleic and Intralipid were stored at room temperature and at 4   and their 
characteristics were investigated over a period of 14 days.  
      Paclitaxel was added to the formulations in increasing concentrations of 1 mg – 6 mg 
per ml of nanoemulsion. The loading efficiency experiments of paclitaxel in 
nanoemulsions were carried out to find the amount of drug the nanoemulsions can 
accommodate and retain.  
          In this chapter, nanoemulsion formulations were characterised in terms of their size, 
zeta potential, polydispersity index, and pH using a range of paclitaxel concentrations. 
Also, the loading efficiency of the drug in nanoemulsions was investigated.  
53 
 
3.1 Size of the nanoemulsion formulations.  
        According to Figure 3.1, the droplet size of both Clinoleic and Intralipid increased 
when more paclitaxel was loaded into the formulations. This indicates the inclusion of the 
drug into the droplets. Droplet size of the Clinoleic emulsion increased from 254.1 nm to 
264.7 nm when paclitaxel (6 mg/ml) was loaded into the formulation, which is a 4.17% 
increase in size. Similarly with the Intralipid emulsion, the measured size was 283.3 nm 
and upon inclusion of 6mg/ml paclitaxel the size increased to 294.6 nm, which is a 3.99% 
increase in size.  
 
 
Figure 3.1: Size between formulations of Clinoleic and Intralipid using a range of 
paclitaxel concentrations (n=3, ± SD) 
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           Statistical analysis showed that the sizes increased significantly for Clinoleic when 
3 mg/ml or more paclitaxel was loaded (P<0.05). However for the Intralipid 
nanoemulsions, the increase in size was significant (P<0.05) only when 6 mg/ml paclitaxel 
was added. The increase of droplet size as a result of drug loading indicates that paclitaxel 
has possibly influenced the interfacial properties of the o/w emulsions, suggesting that 
drug molecules might partially localise at the o/w interface (Nasr et al, 2012). 
Mastropaolo et al, 1995 studied the structure of paclitaxel encapsulated into lipid-carries 
and found that the size of the particles differed from 2 nm to 800 nm and displayed a wide 
variety in shape. This may be another reason why there is an increase in droplet size on 
addition of drug.  
  
 
3.2 Polydispersity Index (PDI) of nanoemulsion formulations 
 
       According to Figure 3.2, the PDI of all nanoemulsion formulations were lower than 
0.2 regardless of emulsion type and paclitaxel concentration. Previous studies using 
extruded liposomes (0.4 µm) showed PI values around 0.5 (Elhissi et al, 2007). This 
indicates that all nanoemulsions were highly homogenous when compared to liposomes.  
 
   For nanoemulsions, the droplets are considered monodispersed if the PDI value is under 
0.2 (Bernardi, 2011). A monodispersed suspension possibly means that the drug paclitaxel 
is accommodated in the bulk of the oil droplets and is not leaking out of the nanoemulsion 
droplets. It is hence expected that if paclitaxel was leaking out (i.e. located at the aqueous 
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phase or the interfacial region of the emulsion), the PDI might become higher as paclitaxel 
crystals have different shape and size compared to nanoemulsion droplets.  
 
 
Figure 3.2: PDI values for the Clinoleic and Intralipid nanoemulsions (n=3, ± SD).  
 
       There was a 16.6 % rise in the PDI of Clinoleic when 6mg/ml paclitaxel was added. 
By contrast there was an increase by 39.25% in the PDI of Intralipid when 6mg/ml of 
paclitaxel was added. This indicates that Clinoleic retains its homogeneity more 
successfully compared to the Intralipid emulsions on addition of paclitaxel. 
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       The greater size and higher PDI of the Intralipid droplets for both drug-free and 
loaded nanoemulsions suggests that the different ingredients had an influence on the size 
and size distribution of the nanoemulsion droplets.  
 
 
Figure 3.3: TEM photograph of the Clinoleic formulation with a paclitaxel 
concentration of 3 mg/ml.  
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        Figure 3.3 shows a TEM image of the Clinoleic nanoemulsion (with a paclitaxel 
concentration of 3mg/ml).  The size according to the scale provided matches with the size 
obtained from the characterization study shown in Figure 3.1 (approximately 250 nm). It 
is apparent that the size of the droplets are evenly arranged, this is confirmed by the PDI 
values shown in Figure 3.2. Some aggregates are also observed in the image, these occur 
as the sample tends to dry whilst capturing the image. Also, phospholipid bilayers are 
observed within the droplets, which are formed due to the presence of egg phosphatides in 
the Clinoleic TPN. 
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Figure 3.4: TEM image of the Intralipid nanoemulsion with a paclitaxel 
concentration of 3mg/ml.  
     According to Figure 3.4, the size of the Intralipid formulation (with a paclitaxel 
concentration of 3mg/ml) is in the range of 250-300 nm according to the scale provided, 
hence confirming the results obtained in Figure 3.1.  But the droplets are not evenly 
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arranged, hence leading to a higher PDI value (as confirmed in Figure 3.2). The larger 
droplets observed in the picture are air bubbles.  
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3.3 pH of Nanoemulsion formulations  
   The pH values for the Clinoleic formulations were slightly more basic than those of the 
Intralipid nanoemulsions (Figure 3.5). For both nanoemulsions, the influence of paclitaxel 
concentration on the measured pH was minimal with no specific trend of increase or 
decrease of pH as a result of drug inclusion. However, although influence of paclitaxel on 
pH seemed minimal for both nanoemulsions, the statistical analysis indicate that 
difference in pH was not significant (P>0.05) only for the Intralipid formulations.  But, it 
was significant for the 3mg/ml sample from the Clinoleic formulations (P>0.05).  
 
 Figure 3.5: pH of Clinoleic and Intralipid nanoemulsions using a range of paclitaxel 
concentrations (n=3, ± SD).  
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        The pH of blood in humans is approximately 7.365. Hence if these formulations are 
to be injected intravenously, their pH also needs to be similar to the biological pH. A pH 
value in the range of 6.0-8.0 is considered ideal for intravenous administration. This 
clearly suggests that these nanoemulsions would be suitable for intravenous administration 
with accordance to pH values.  
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3.4 Zeta Potential (ZP) of Nanoemulsion formulations. 
    The zeta potential of Clinoleic has a higher negative intensity than that of Intralipid 
(Figure 3.6). The values for Intralipid are closer to neutral. This reason for this might be 
that Olive oil carries a ZP value closer to 0, which Soybean oil always carries a positive 
ZP. The values for Intralipid using paclitaxel (2 mg/ml and 4 mg/ml) are significantly 
higher (P<0.05) than that of the drug-free Intralipid emulsion. The ZP values for Clinoleic 
as well show a trend of decrease in the negative intensity. This indicates that paclitaxel 
had an influence on the surface charge of the nanoemulsion droplets.  
 
Figure 3.6: ZP values of Clinoleic and Intralipid nanoemulsions using a range of 
paclitaxel concentrations (n=3, ± SD).  
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             It has been previously reported that the zeta potential of a nanoemulsion 
formulation depends on its pH. If the pH is high (i.e. basic), the ZP value is likely to be 
negative and if the pH is low (acidic), the ZP value will be neutral or positive (Poluri et 
al., 2011). For example in a  recent study the ZP value of emulsified soybean oil decreased 
from +12mV to -20mV when the pH was increased from 2.0 to 8.0 (Iwanaga et al, 
2007)Thus the more negative zeta potential values of the Clinoleic emulsions might be 
justified by the higher pH values of this emulsion compared with the Intralipid emulsions 
(Figure 3.6).  
   For a nanoemulsion formulation to be electro-statically stable so that it is not susceptible 
to coalescence or breaking during storage, the ZP values should be close to or over ±30 
mV (Elsheikh et al., 2012).  As the values for Clinoleic are closer to ±30 mV than the ZP 
values of Intralipid, it can be concluded that Clinoleic might be more electro-statically 
stable. Long-term stability studies using paclitaxel with Clinoliec or Intralipid emulsions 
are needed to verify if this assumption is correct.  
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3.5 Stability of Nanoemulsion formulations.  
3.5.1 Formulations stored at 4 C 
         Figure 3.7 represents the variations in size when a formulation is stored at 4   for 
two weeks. For Clinoleic, the size showed a trend to increase slightly but was not 
significant (P>0.05), indicating that size of droplets of this emulsion did not change upon 
storage for two weeks at 4   .  he minimum droplet size of the emulsion being 254.3 nm 
and the maximum was 258.7 nm when analysis was performed on freshly prepared 
samples and those stored for two weeks at 4  . 
 
Figure 3.7: Size analysis of Clinoleic and Intralipid formulations stored at 4 C using a 
range of paclitaxel concentrations (n=3, ± SD) 
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        Intralipid formulations showed an increase in the droplet size over the two-week 
period of storage at 4°C (Figure 3.7). The minimum size measured was 285.6 nm on 
freshly prepared samples and the maximum was 311.7 on day 14. The statistical analysis 
on the Intralipid emulsions has shown that the slight increase was statistically significant 
(P>0.05). 
 
 
Figure 3.8: pH analysis of Clinoleic and Intralipid nanoemulsions containing a range 
of paclitaxel concentrations when stored at 4 C for two weeks (n 3,    D) 
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     Figure 3.8 represents the pH values for Clinoleic and Intralipid nanoemulsions as 
freshly prepared and upon storage for 14 days at 4  .  linoleic formulations did not show 
any change in pH values but the Intralipid formulations showed a significant (p<0.05) 
decrease in the values after 14 days storage when compared to the freshly prepared 
samples, suggesting that the formulations have become acidic. For both nanoemulsions, 
the paclitaxel concentration had no effect or only a slight effect on the pH, indicating that 
it is the length of storage which affects the pH of these emulsions.  
 
 
Figure 3.9: Zeta potential analysis of Clinoleic and Intralipid nanoemulsions upon 
storage for two weeks at 4 C (n 3,    D).  
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     Figure 3.9 shows the changes in  P that occur when nanoemulsion formulations are 
stored at 4   for two weeks.  here were no significant differences in the  P vales for 
either nanoemulsion.   
     
 
3.5.2 Formulations stored at room temperature  
        The size of the Clinoleic droplets (Figure 3.10) showed a trend of slight increase 
when stored at room temperature, indicating that some of the paclitaxel might have 
collected at the surface of the droplets. However, the size of the Intralipid droplets 
increased significantly (P<0.05) suggesting that more paclitaxel has localised near the 
surface if the nanoemulsion droplets.  
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Figure 3.10: Size analysis of Clinoleic and Intralipid formulations stored at room 
temperature for a 14 days (n=3, ± SD). 
 
        The PDI values for the Intralipid also increased from 0.175 ± 0.026 to 0.225 ± 0.031 
when stored at RT for two weeks. This is a significant (P<0.05) increase in PDI which 
confirms that paclitaxel is causing droplet aggregation by locating at the surface of the 
droplets, causing them to be more hydrophobic and hence more liable to aggregation. 
When these values are compared with those of the formulations stored at 4  , it is evident 
that the size and PDI increased more when stored at   , suggesting that the formulations 
are more stable when stored at 4  . 
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   As shown in Figure 3.11 the pH of nanoemulsion formulations was highly dependent on 
storage and nanoemulsion type rather than paclitaxel concentration. This was manifested 
by the significant decrease (P<0.05) in pH of the Clinoleic and Intralipid formulations 
when stored at RT for 14 days (Figure 3.11)  
 
Figure 3.11:  Changes in pH for the Clinoleic and Intralipid formulations when 
stored for two weeks at RT (n=3, ± SD).  
         When the above pH values are compared with the pH values of the formulations 
stored at 4   (Figure 3.8 , it is apparent that the pH has decreased more when the 
nanoemulsions were stored at   ; the pH at 4 c is in the range of 6.0-7.0.  his advocates 
that the formulations are more stable when stored at 4   as already confirmed via the size 
and PDI results. The reason for the decrease in pH might be the conversion of the olive oil 
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and soybean oil to Fatty acids at RT. Although this reaction might still be happening at 4° 
C, it will be faster at RT due to the higher temperature. Acids tend to have a lower pH 
(Scrimgeour, 2005); hence the pH of the whole formulation decreases after storage at RT.  
 
 
 Figure 3.12: Changes in ZP values for the Clinoleic and Intralipid formulations 
when stored for two weeks at RT (n=3, ± SD).  
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      As discussed earlier, the ZP of nanoemulsions depends on its pH. According to Figure 
3.11 the pH decreases for both the nanoemulsions and as a result the ZP increases. This 
correlates well with the finding in Figure 3.12. There is a trend of great variability in the 
results indicating instabilities.  
         Bernardi et al (2011  stored o w nanoemulsion at three different temperatures: 25   2 
 , 40   2   and 5   2   to test the nanoemulsions storage stability. After 90 days, they 
found that the droplet size had remained constant and the PDI was also below 0.2 
indicating that the nanoemulsion formulations were stable at all temperatures. Only the pH 
reading had reduced for the sample stored at 40   2  , but the pH was still in the range of 
6.0-8.0. However, no drug was used in this experiment; all the formulations were drug-
free. Hence, it is possible that it is the paclitaxel present in the Clinoleic and Intralipid 
nanoemulsions that makes the formulation unstable when stored at room temperature. 
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3.6 Loading Efficiency of nanoemulsion formulations.  
        A calibration curve was plotted to obtain the equation and R
2 
value for paclitaxel as 
shown in Figure 3.13. As the concentration increases, the absorbance linearly increases. 
Using the equation and R
2 
value, the entrapped paclitaxel in each nanoemulsion 
formulation was found.  
 
 
Figure 3.13 Calibration curve showing the absorbance plotted against the 
concentration of paclitaxel per 100 ml of ethanol.  
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Figure 3.14: Loading efficiency of paclitaxel in nanoemulsion droplets using the 
Clinoleic and Intralipid nanoemulsions (n=3 ± SD).  
 
                  Loading efficiency of paclitaxel in the nanoemulsion was dependent on type of 
nanoemulsion and concentration of drug (Figure 3.14). In the Clinoleic nanoemulsions 
70.4 ± 3.5 % (0.704 ± 0.035 mg/ml), 80.2 ± 4.2 % (2.46 ± 0.126 mg/ml) and 77.3 ± 2.5 % 
(4.63 ± 0.15 mg/ml) were successfully loaded into the emulsion droplets using 1mg/ml, 
3mg/ml and 6 mg/ml paclitaxel respectively. By contrast for the Intralipid emulsion, lower 
loading efficiencies for the drug were observed. These were 57.38 ± 4.7% (0.57 ± 0.047 
mg/ml), 52.5 ± 5.6 % (1.57 ± 0.17 mg/ml) and 44.2 ± 3.1 % (2.65 ± 0.19 mg/ml) for the 
1mg/ml, 3 mg/ml and 6 mg/ml paclitaxel formulations respectively.  
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    According to a recent study, paclitaxel is not highly soluble in soybean oil; showing a 
solubility of only 0.18 mg/ g of soybean oil (Surapareni et al, 2012; Kan et al, 1999). On 
the other hand, paclitaxel shows a solubility of 0.6 mg/ml in Oleic acid, which is the main 
component of Olive oil (Singla et al, 2002). Intralipid emulsion is composed of mainly 
soybean oil but Clinoleic emulsion only has 20% soybean oil, this may be a reason for the 
higher loading efficiency observed in Clinoleic formulations.  
   Clinoleic emulsion also has a few extra ingredients than Intralipid emulsion. It is 
possible that the extra components: Essential fats acids and Sodium oleate, allow the 
Clinoleic nanoemulsion to solubilise and retain more paclitaxel.  
 
      Paclitaxel is a hydrophobic drug and has a solubility of less than 0.1 µg/ ml in aqueous 
solutions (Konno et al., 2003). By using Clinoleic and Intralipid, the solubility of 
paclitaxel was enhanced to 4.63 mg/ml and 2.65 mg/ml respectively (Figure 3.14).  
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Chapter 4: 
Tissue Culture 
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     A nanoemulsion is a heterogeneous dispersion of nano-sized (1-1000 nm) oil droplets 
in water. The advantage of using nanoemulsions in cell culture is that it increases the 
cellular uptake of oil-soluble supplements or drugs (Shah et al, 2009). Nanoemulsions 
increase the bioavailability of the drug to the cells. Paclitaxel is widely used anti-cancer 
drug. It hydrophobic drug but it dissolves readily in the oil phase of nanoemulsions 
(Surapaneni et al, 2012).  
      Tissue culture can be defined as the in vitro growth of cells, obtained from multi-
cellular organisms, in a controlled environment. The U87-MG and SVG-P12 cell lines 
were used for this experiment as model cancerous and normal cells respectively. U87-MG 
(Human glioblastoma –astrocytoma) are grade IV glioma cells, while SVG-P12 are 
normal human brain cells (astrocytes).    
  Poly-L-lysine (PLL) and Dextran were used as positive and negative controls 
respectively. A positive control is well-established and should be toxic to cells in tissue 
culture. By contrast, a negative control is a test that confirms that a given compound has 
very little or no effect on the cells.  
   This experiment was divided into two parts: Growth curves and Cytotoxicity tests. In the 
first part the cells were seeded in the densities of 10
3
, 10
4
 and 10
5
 cells per well and 
allowed to grow for seven days. The absorbance was measured every day. The aim of this 
experiment was to find the most appropriate seeding density for the cytotoxicity tests. The 
appropriate seeding density in this case is one that gives a relatively high absorbance value 
(0.7-0.9) for pure media (MEM). Only if the absorbance is sufficiently high, the cytotoxic 
effects of formulations can be properly detected.   
  The next part of the experiment was to carry out the MTT (cytotoxicity) assays. MTT (3-
(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) is a yellow tetrazole 
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compound  that  is reduced to purple formazan crystals by living cells. Hence the amount 
of purple formazan crystals in a given well (of a 96 well plate) is an indicator of the 
number of living cells in that well. DMSO was used to solubilize the crystals and obtain a 
bluish-purple coloured solution; the absorbance of which was measured at 612 nm.  
  In this study the cytotoxicity of a range of paclitaxel formulations was investigated using 
Clinoleic nanoemulsions, Intralipid nanoemulsions and paclitaxel solution.  SVG-P12 
cells and U87-MG cells were used as model normal cells and cancerous cells respectively.  
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4.1 Growth Curves 
   In this study the percentage growth of cells using a range of seeding densities was 
compared for the SVG-P12 cells (Figure 4.1). The growth for the SVG-P12 using a 
seeding density of10
3
 cells/ well increased to nearly 200 ± 6.86% but the absorbance 
readings were only in the range of 0.1-0.15 at day 7.By contrast, the growth using 10
4
 
cells/well seeding density increased to approximately 261 ± 7.9% and the absorbance 
readings were in the range of 0.27-0.31 units at day 7. However, when the seeding density 
was 10
5
 cells/well, the percentage growth for the SVG-P12 was 256 ± 8.72 % and the 
absorbance reading was in the range of 0.7-0.75. 
Figure 4.1: Percentage growth of the 10
3
, 10
4
 and 10
5 
seeding densities of the SVG-
P12 cell line.  
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      Hence the 10
5 
cells/well seeding density was the most appropriate as it has the highest 
rate of cell proliferation and had optimal absorbance readings at the final day (Figure 4.1). 
The absorbance values for the growth curves were significantly different for all seeding 
densities measured at each day (P<0.05).   
   The percentage growth for the 10
5 
cells/well density was less than the percentage growth 
of the 10
4 
cells/well density on day 7. This was due to the limited space and nutrients in 
the well. 
 
Figure 4.2: Microscopic photographs showing the SVG-P12 cells using three 
different seeding densities [10
5 
(A), 10
4
 (B) and 10
3 
(C)].  
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Figure 4.2 shows the inverted light microscopic images of the SVG-P12 cells at three 
different seeding densities. The images are in accordance with the growth curves obtained 
via the absorbance readings (Figure 4.1) as the number of cells per well is directly 
proportional to the absorbance or cell viability. The highest number of cells is observed in 
the 10
5
 cells/well seeding density and the lowest in the 10
3
 seeding density.  
    
      According to Figure 4.3, the seeding density of 10
3
 cells/ well caused a cellular growth 
by nearly 222 ± 6.55% but the absorbance readings were only in the range of 0.1-0.15 
units at day 7. By contrast, the growth for the 10
4
 cells/well density was approximately 
292 ± 5.5 % and the absorbance readings were in the range of 0.31-0.35 at day 7. 
However, the growth percentage for the 10
5
 cells/well density was 282.5 ± 6.15 % and the 
absorbance was in the range of 0.94-0.97. 
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Figure 4.3: Percentage growth using 10
3
, 10
4
 and 10
5 
seeding densities of the U87-MG 
cell line.  
 
  Thus the 10
5 
cells/well seeding density is most appropriate due to the fast rate of growth 
and the high absorbance readings.  The absorbance values were significantly different 
(P<0.05) when compared with the corresponding day of the other two seeding densities, 
(e.g., day 4).  
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 As seen with SVG-P12 cells, the growth for the 10
5 
cells/well density is less compared to 
the growth of the 10
4 
cells/well density on day 7 as well. This is also due to the limitation 
of space and nutrients in the well as previously explained.  
 
Figure 4.4: Microscopic photographs showing the U87-MG cells using three different 
seeding densities [10
5 
(A), 10
4
 (B) and 10
3 
(C)]. 
     Figure 4.4 shows the inverted light microscopic images of the U87-MG cells at three 
different seeding densities. The images are in accordance with the growth curves obtained 
via the absorbance readings (Figure 4.3) as the number of cells per well is directly 
proportional to the absorbance or cell viability. The highest number of cells is observed in 
the 10
5
 cells/well seeding density and the lowest in the 10
3
 seeding density.  
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4.2 MTT Assays for assessing the cytotoxicity of formulations.  
 
           The negative control Dextran did not have any toxic effect on the glial cells as 
expected. In fact a very slight growth of the cells was observed from 100% to 105.6 ± 
1.02% when 5mg of dextran per ml of media was added (Figure 4.5). Conversely, the 
positive control PLL had a very toxic effect on the cells and the cell viability dropped to 
5.12 ± 3.17 % when 5 mg of PLL was added per ml of media. Paclitaxel also had a similar 
effect on the cells as PLL; the cell viability rate dropped to 4.95 ± 2.1% when 6 mg of 
Paclitaxel was added per ml of media.  
  
84 
 
 
   
Figure 4.5: Cytotoxic effects of the formulations on the SVG-P12 cells: Dextran, 
Blank Clinoleic, Blank Intralipid, Clinoleic loaded with paclitaxel, Intralipid loaded 
with paclitaxel, PLL and Paclitaxel.  
 
        In the case of Blank nanoemulsions (Clinoleic and Intralipid) – they acted as negative 
controls as they were expected not to have toxic effects on the glial cells (Figure 4.5). 
These drug-free nanoemulsions however caused a slight increase in the growth of the 
cells. Blank Clinoleic lead to an increase in the cell viability of SVG-P12 cells by 101.3 ± 
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0.95% which happened when the cells were supported by the drug-free Clinoleic 
formulation instead of MEM as nutrition. Similarly, Blank Intralipid increased the cell 
viability from 100% to 104.32 ± 1.04% (Figure 4.5).  
 
   When Clinoleic loaded with paclitaxel was applied to the cells, the cell viability 
decreased to 34.57 ± 1.9 % for the concentration of 6 mg of paclitaxel per ml of the media. 
Similarly, Intralipid loaded with paclitaxel lowered the cell viability to 26.04 ± 1.06%. 
Although the entrapment efficiency of Clinoleic emulsion is higher, its cell toxicity is 
slightly lower than Intralipid emulsion (Figure 3.14). The reason for this may be that 
Clinoleic is able to retain drug for a longer period (>72 hours) and releases it in the 
external phase from the droplets slowly. The reason for this sustained release of paclitaxel 
might be the difference in the constituents as Paclitaxel is more soluble in Olive oil than it 
is in soybean oil.  
 
     There is a noticeable difference between cell viability values of the nanoemulsions 
containing paclitaxel and paclitaxel on its own. Paclitaxel by itself is more toxic to the 
cells compared to when it is loaded inside the nanoemulsions. As these are normal glial 
cells, lower cytotoxicity is highly desirable indicating that paclitaxel loaded in 
nanoemulsions was advantageous to paclitaxel alone. The nanoemulsion formed a 
protective barrier between the cells and paclitaxel; hence they showed lower cell toxicity 
than paclitaxel by itself.  
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     There is a significant difference between the absorbance readings obtained for 
Paclitaxel and the nanoemulsions (Clinoleic and Intralipid) loaded with paclitaxel 
(P<0.05).  
 
 
Formulation IC50 Value (mg) ± SD 
Paclitaxel 0.26 ± 0.02 
PLL 0.40 ± 0.024 
Intralipid with Paclitaxel 2.7 ± 0.43 
Clinoleic with Paclitaxel 3.7 ± 0.18 
Table 4.1: IC50 Values of the formulations in mg for SVG-P12 cells 
     According to Table 4.1, it is seen that paclitaxel by itself has the lowest IC50 value 
indicating that it has the highest cytotoxicity followed by PLL, Intralipid with paclitaxel 
and Clinoleic with paclitaxel in that order. This means that only 0.026 mg of paclitaxel 
alone was required to kill 50% of the SVG-P12 cells. By contrast, 2.7 mg of paclitaxel 
loaded in Intralipid and 3.7 mg of paclitaxel loaded in Clinoleic was required to kill the 
same amount of cells. The reason for this may be attributed to the protective external 
phase barrier between the cells and the drug-loaded oil droplets (Surapaneni et al, 2012).  
  There is a significant difference between all the IC50 values when compared with one 
another (P<0.05).  
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Figure 4.6: Inverted light microscopic photographs of SVG-P12 cells treated with 
Clinoleic containing paclitaxel. These images show the declining number of cells as 
more paclitaxel is added per ml of media. [0.0 mg (A), 0.5 mg (B), 1.5 mg (C) and 3 
mg (D) per ml] 
 
The images above agree with the findings presented in Figure 4.5, as it confirms that as 
the concentration of paclitaxel (entrapped in Clinoleic) increased, the number of viable 
cells decreased.  
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Figure 4.7: Inverted light microscopic images of SVG-P12 cells treated with 
Intralipid containing paclitaxel. These images show the decreasing number of cells as 
higher concentrations of paclitaxel were added [0.0 mg (A), 0.5 mg (B), 1.5 mg (C) 
and 3 mg (D) per ml].  
 
The images above agree with the scatter plot (Figure 4.2.1) as it confirms the converse 
relationship between paclitaxel concentration (entrapped in Intralipid) and the number of 
viable cells.  
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Figure 4.8: U87-MG showing the cytotoxic effects of the formulations in percent 
cytotoxicity: Dextran, Blank Clinoleic, Blank Intralipid, Clinoleic loaded with 
paclitaxel, Intralipid loaded with paclitaxel, PLL and Paclitaxel 
 
         As seen with SVG-P12, the negative control Dextran did not have any toxic effect 
on U87-MG as well; and slightly aided in the growth of the cancerous cells. The cell 
viability increased from 100% to 113.34 ± 8.11% for the 5mg/ml Dextran concentration. 
On the contrary, the positive control PLL had a very toxic effect on the cells as expected. 
The cell viability dropped to 7.01 ± 1.17 % for PLL. Paclitaxel being an established anti-
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cancer agent also has a similar effect on the cells as PLL; the cell viability rate dropped to 
3.67 ± 0.87%.  
      
   When the blank nanoemulsions (Clinoleic and Intralipid) were used, their effect on the 
viability of the cancerous cells was similar to that on SVG-P12 cells. They had no 
cytotoxic effects but actually assisted in the growth of the cells. Blank Clinoleic increased 
the viability of U87-MG cells to 104.64 ± 8.91%. Similarly, the blank Intralipid increased 
the viability from 100% to 105.29 ± 5.35% 
 
   When Clinoleic loaded with paclitaxel was introduced to the U87-MG cells, the cell 
viability decreases to 6.4 ± 2.3 % for the concentration of 6 mg of paclitaxel per ml of 
media. Similarly, Intralipid loaded with paclitaxel lowered the cell viability to 21.29 ± 
3.82%. Clinoleic killed more cancerous cells than Intralipid emulsions; this might be due 
to the higher entrapment efficiency of Clinoleic formulations (Figure 3.14). Another 
reason may be the different components that these two nanoemulsions are comprised of 
leading to different rates of drug-release.  
     
     There is a very small difference between the cell viability values for nanoemulsions 
with paclitaxel and paclitaxel by itself.  This shows that both efficiently inhibit or destroy 
the grade IV glioma cells. As these are Grade IV glioblastoma cells, lower cell viability is 
the desired result.  
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  There is a significant difference between the absorbance readings of the positive and 
negative controls (P<0.05). But when the readings for Blank Clinoleic, Blank Intralipid 
and Dextran are compared, there is no significant difference. But these three compounds 
are significantly distinct from the absorbance readings obtained for Paclitaxel and the 
nanoemulsions (Clinoleic and Intralipid) loaded with paclitaxel (P<0.05).  
    
      Both drug-loaded Clinoleic and Intralipid nanoemulsions killed a greater number of 
U87-MG cells than normal glial SVG-P12 cells. A possible reason for this may be that as 
cancerous cells divide and multiply faster, their intake of the nutrients in the surrounding 
media is also faster (Miller et al, 2007). Hence the U87-MG cells are exposed to more 
paclitaxel than the SVG-P12 cells, leading to higher cell death.  
 
Formulations IC50 value 
Paclitaxel 0.092 ± 0.009 
PLL 0.33 ± 0.042 
Clinoleic with paclitaxel 0.66 ± 0.05 
Intralipid with paclitaxel 1.8 ± 0.29 
Table 4.2: IC50 Values of the formulations in mg for U87-MG cells 
 
        Paclitaxel by itself has the lowest IC50 value indicating that it has the highest 
cytotoxicity followed by PLL, Clinoleic with paclitaxel and Intralipid with paclitaxel 
respectively. There is a significant difference between all the IC50 values when compared 
with one another (P<0.05).  
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 Figure 4.9: Inverted light microscopic images of U87-MG cells treated with Clinoleic 
containing paclitaxel. These images show the dwindling number of cells as more 
paclitaxel was added. [0.0 mg (A), 0.5 mg (B), 1.5 mg (C) and 3 mg (D) per ml].  
 
 
       The images above agree with Figure 4.8 demonstrating the influence of higher 
paclitaxel (in Clinoleic nanoemulsions) concentration on the viability of cells.  
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Figure 4.10: Inverted light microscopic images of U87-MG cells treated with 
Intralipid containing paclitaxel. These images show the dwindling number of cells as 
more paclitaxel was added. [0.0 mg (A), 0.5 mg (B), 1.5 mg (C) and 3 mg (D) per ml]. 
 
       Similarly, the images above (Figure 4.10) also agree with the cytotoxicity curve 
(Figure 4.8) as it confirms that as the concentration of paclitaxel (encapsulated in 
Intralipid) increases, the number of viable cells decreases.  
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     When compared with each other, Clinoleic is more potent in decreasing the number of 
U87-MG cells as compared to Intralipid; but it is less toxic to the SVG-P12 cells. The 
amount of paclitaxel required (IC50 value) for Clinoleic to kill 50% of U87-MG cells is 
0.66 ± 0.05 mg/ml, while it takes 3.7 ± 0.18 mg/ml of the same to destroy 50% of SVG-
P12 cells. Similarly, the amount of paclitaxel required (IC50 value) for Intralipid to kill 
50% of U87-MG cells is 1.8 ± 0.29 mg/ml, while it takes 2.7 ± 0.43 mg/ml of the same to 
destroy 50% of SVG-P12 cells. Paclitaxel is highly toxic to both cell lines having an IC50 
value of 0.092 ± 0.009 mg/ml against U87-MG and 0.26 ± 0.02 mg/ml against SVG-P12 
cells. Both nanoemulsions are less toxic to the normal glial cells (SVG-P12) than 
paclitaxel alone, but Clinoleic has noticeably milder toxicity to the SVG-P12 cells.  
    As discussed earlier, the reasons for the differences in cell toxicity and IC50 values can 
be attributed to the different components of the two nanoemulsions, different loading 
efficiencies and the faster cell proliferation of the U87-MG cells. The higher loading 
efficiency and sustained release of paclitaxel by the Clinoleic emulsion makes it a superior 
emulsion than Intralipid for in vitro glioma therapy with paclitaxel.  
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Chapter 5: 
Conclusions and Future prospects 
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5.1 General conclusions  
 
 Comparison of characteristics of the Clinoleic and Intralipid nanoemulsions 
 
       The droplet size of both Clinoleic and Intralipid formulations increased as 
higher Paclitaxel concentrations were included. Droplet size of the Clinoleic 
emulsion was increased from 254.1 nm for drug-free nanoemulsions to 264.7 nm 
when paclitaxel (6 mg/ml) was loaded into the formulation. Similarly with the 
Intralipid, the measured size was 283.3 nm and upon inclusion of 6mg/ml 
paclitaxel the size increased to 294.6 nm. The increase of droplet size as a result of 
drug loading indicates that paclitaxel has possibly influenced the interfacial 
properties of the o/w emulsions, suggesting that drug molecules might partially 
localise at the o/w interface.  
 
     The PDI of all nanoemulsion formulations (Clinoleic and Intralipid) were lower 
than 0.2 irrespective of paclitaxel concentration indicating that all the 
nanoemulsion formulations were homogenous. There was a 16.6 % rise in the PDI 
of Clinoleic when 6mg/ml paclitaxel was added. By contrast there was an increase 
by 39.25% in the PDI of Intralipid when 6mg/ml of paclitaxel was added. This 
indicates that Clinoleic retains its homogeneity more successfully compared to the 
Intralipid emulsions on addition of paclitaxel.  
 
             The pH values for the Clinoleic formulations (7.1-7.5) were slightly more 
basic than those of the Intralipid formulations (6.5-6.9). For both nanoemulsions, 
the influence of paclitaxel concentration on the measured pH was minimal; with no 
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specific trend of increase or decrease in pH as a result of drug inclusion. A pH 
value in the range of 6.0-8.0 is considered ideal for intravenous administration. 
This clearly suggests that these nanoemulsions would be suitable for intravenous 
administration with accordance to the pH values.  
 
     The ZP of Clinoleic has a greater negative intensity than that of Intralipid. The 
values for Intralipid are closer to neutral. However, on addition of paclitaxel (2 
mg/ml and 4 mg/ml) the intensity of the charge decreased substantially for 
Intralipid when compared to the drug-free formulation.  This indicates that 
paclitaxel had an effect on the surface charge of the Intralipid droplets.  
 
   For a nanoemulsion formulation to be electro-statically stable during storage (so 
that it is not susceptible to coalescence or phase separation), the ZP values should 
have a high intensity; preferably over ±30 mV (Elsheikh et al., 2012). As the ZP 
values for Clinoleic are closer to ±30 mV as compared to Intralipid, it can be 
concluded that Clinoleic might be more electro-statically stable than Intralipid.   
 
      Clinoleic is composed of refined olive oil, refined soybean oil, essential fatty 
acids, purified egg phosphatides, glycerol, sodium oleate and sodium hydroxide. 
While Intralipid contains purified soybean oil, purified egg phospholipids, glycerol 
anhydrous and sodium hydroxide. The difference in the composition of the 
nanoemulsions may be responsible for the difference in size, ZP, pH and PDI.  
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 Clinoleic formulations are more stable than Intralipid formulations. 
 
After 14 days of storage at 4   the droplet size of  linoleic nanoemulsion 
increased from 254.3 to 258.7 nm, which is not a substantial increase. On the other 
hand, Intralipid droplet size increased from 285.6 to 311.7 nm after 14 days of 
storage at 4  , which is a significant increase in size.  here is no significant 
difference in the PDI values for both nanoemulsions upon storage for 14 days at 4 
 .  he pH of  linoleic did not show any change when stored at 4   for two weeks, 
but the Intralipid formulations showed a downwards trend as the pH values 
became more acidic after 14 days. For both nanoemulsions, paclitaxel 
concentration had very little or no effect on the pH, indicating that it is the length 
of the storage which affects the pH of these formulations. When stored at 4   no 
significant difference in the ZP values for both nanoemulsions after 14 days was 
detected. 
  
     When stored at room temperature, all the formulations (of Clinoleic and 
Intralipid) showed a trend of increase in droplet size after 14 days, indicating that 
some of the paclitaxel may have leaked out of the droplets and located at the 
interface, causing the droplet‟s surface to become more hydrophobic with a 
subsequent aggregation. The PDI values for the Clinoleic formulations did not 
show much change, but the PDI values for the Intralipid formulations increased 
from 0.175 ± 0.026 to 0.225 ± 0.031 after two weeks at room temperature. There is 
a significant increase in PDI that confirms that paclitaxel is causing droplet 
aggregation by localizing at the surface of the droplets and increasing their 
hydrophobicity; hence they are more prone to form aggregates. The pH for both 
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the Clinoleic and Intralipid formulations also decreased considerably when stored 
at RT for two weeks; it reduced to below 6.0 in both cases reducing their 
suitability for intravenous administration. There is a trend of decrease in the 
intensity of the ZP values of both Clinoleic and Intralipid when stored at RT for 14 
days which is in accordance with the decrease in the pH readings.  
 
      All the characteristics showed greater variances in their measurements when 
stored at    and it is apparent that the nanoemulsions are generally more stable 
when stored at 4  .  linoleic showed more stability than Intralipid formulations 
when stored at both    and 4  .  his stability can be attributed to the presence of 
sodium oleate in Clinoleic TPN. Sodium oleate is a commonly used emulsifier 
(surfactant) which has been known to improve the stability of emulsions. 
 
 Clinoleic has better loading efficiency for Paclitaxel as compared to Intralipid. 
 
            In the Clinoleic formulations 70.4 ± 3.5 % (0.704 ± 0.035 mg/ml), 80.2 ± 
4.2 % (2.46 ± 0.126 mg/ml) and 77.3 ± 2.5 % (4.63 ± 0.15 mg/ml) of paclitaxel 
was successfully loaded into the droplets for the 1 mg/ml, 3 mg/ml and 6mg/ml 
paclitaxel concentrations respectively.  Conversely, lower loading efficiencies 
were obtained for the Intralipid formulations: 57.38 ± 4.7% (0.57 ± 0.047 mg/ml), 
52.5 ± 5.6 % (1.57 ± 0.17 mg/ml) and 44.2 ± 3.1 % (2.65 ± 0.19 mg/ml) of 
paclitaxel was successfully loaded into the droplets for the 1 mg/ml, 3 mg/ml and 6 
mg/ml Intralipid formulations respectively.  
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    Clinoleic TPN is comprised of more ingredients when compared to Intralipid 
TPN; these are refined olive oil, essential fatty acids and sodium oleate. These 
ingredients may be responsible for the improved loading efficiency of paclitaxel in 
the Clinoleic emulsions. Olive oil has been proven to be a better alternative to 
soybean oil for emulsions in previous studies (Gobel et al., 2003; Deshpande et al., 
2009).  
 
 Clinoleic formulations show greater toxicity towards Grade IV glioma cells 
(U87-MG) 
 
     When Clinoleic loaded with paclitaxel was introduced to the U87-MG cells, the 
cell viability decreased to 6.4 ± 2.3 % for the concentration of 6 mg of paclitaxel 
per ml of media. Similarly, Intralipid loaded with paclitaxel lowered the cell 
viability to 21.29 ± 3.82%. The IC50 values for paclitaxel loaded into Clinoleic and 
Intralipid were 0.66 ± 0.05 and 1.8 ± 0.29 respectively indicating that Clinoleic 
loaded with paclitaxel was more toxic towards the glioma cells.  This difference in 
cytotoxicity may be due to the higher entrapment efficiency observed in the 
Clinoleic formulation (Figure 3.14) 
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 Intralipid formulations show greater toxicity towards normal glial cells (SVG-
P12) 
 
        When Clinoleic loaded with paclitaxel was added to the SVG-P12 cells, their 
viability decreased to 34.57 ± 1.9 % for the concentration of 6 mg of paclitaxel per ml of 
media. Similarly, Intralipid loaded with paclitaxel lowered the cell viability of SVG-P12 
to 26.04 ± 1.06%. Also, 2.7 ± 0.43 mg of paclitaxel loaded in Intralipid was required to 
kill 50% of the normal glial cells whilst 3.7 ± 0.18 of paclitaxel loaded in Clinoleic was 
required to do the same effect. This indicates that Intralipid loaded with paclitaxel shows 
greater toxicity towards the SVG-P12 cells. The reason for this may be that Clinoleic is 
able to retain drug for a longer period (>72 hours) and releases it in the external phase 
from the droplets slowly (Aboofazeli et al, 2003).  
 
 
 
 Both Clinoleic formulations and Intralipid formulations are less toxic than 
Paclitaxel by itself 
 
            Paclitaxel by itself has the lowest IC50 value for U87-MG cells indicating 
that it has the highest cytotoxicity followed by PLL, Clinoleic with paclitaxel and 
Intralipid with paclitaxel. In the case of SVG-P12 cells, paclitaxel by itself has the 
lowest IC50 value indicating that it has the highest cytotoxicity followed by PLL, 
Intralipid with paclitaxel and Clinoleic with paclitaxel. Paclitaxel kills about 95% 
of the SVG-P12 normal glial cells, while paclitaxel in Clinoleic and Intralipid kills 
only around 66% and 74% respectively. This indicates that paclitaxel does not 
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differentiate between normal and glial cells, killing both the normal glial and grade 
IV glioblastoma cells equally. On the other hand the nanoemulsion formulations 
(containing paclitaxel) show sustained release of the drug, killing less SVG-P12 
cells in comparison to the U87-MG cells.  
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5.2 Future work 
        Due to the constraints of time a number of studies were not performed. For 
example, more research can be carried out on the stability of nanoemulsions by storing 
them at higher temperatures (more than 30   . In addition, it would have been useful to 
observe the effects of storing the nanoemulsion formulations for a longer duration at 
various temperatures.  
       Also, it would have been interesting to study the effects of these nanoemulsions on 
an additional cell line for a moderate (grade II) glioma like the 1321N1 cell line.   It 
would also be useful to test these formulations on other cancer cell lines (like breast 
cancer) just to measure the efficacy of the formulations.  
         It would have been very useful to study the potency of the nanoemulsion 
formulations in vivo and compare the results with that of paclitaxel administered via 
another delivery vehicle like Cremophor EL.  
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